严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗接种后复发性亚急性甲状腺炎：一例报告
Recurring subacute thyroiditis after SARS-CoV-2 mRNA vaccine: A case report.
作者信息
Vasileiou Vasiliki, Paschou Stavroula A, Tzamali Xakousti, Mitropoulou Marina, Kanouta Fotini, Psaltopoulou Theodora, Kassi Georgia N
机构信息
Department of Endocrinology, Alexandra Hospital, Athens, Greece.
Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Case Rep Womens Health. 2022 Jan;33:e00378. doi: 10.1016/j.crwh.2021.e00378. Epub 2021 Dec 28.
SARS-CoV-2 vaccination is the most powerful and promising tool against the COVID-19 pandemic. Millions of people have been vaccinated worldwide. Recently, few cases of subacute thyroiditis following SARS-CoV-2 vaccination with various types of vaccine have been reported. We describe here a 36-year-old woman who presented with subacute thyroiditis 10 days after she had received her first dose of the SARS-CoV-2 mRNA vaccine Comirnaty (Pfizer/BioNTech); the condition receded but then recurred 10 days after she received her second dose. As vaccination programmes proceed, clinicians' attention and vigilance for such cases will be increased. Physicians need to know that subacute thyroiditis is a mild and self-limiting condition in the majority of cases. Last but not least, the benefits of vaccination against COVID-19 outweigh the side-effects reported so far.
接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗是对抗2019冠状病毒病（COVID-19）大流行最有力且最具前景的工具。全球已有数百万人接种了疫苗。最近，有报道称接种不同类型的SARS-CoV-2疫苗后出现了几例亚急性甲状腺炎病例。我们在此描述一名36岁女性，她在接种第一剂SARS-CoV-2信使核糖核酸（mRNA）疫苗Comirnaty（辉瑞/ BioNTech）10天后出现亚急性甲状腺炎；病情缓解，但在接种第二剂10天后复发。随着疫苗接种计划的推进，临床医生对此类病例的关注和警惕性将会提高。医生需要了解，亚急性甲状腺炎在大多数情况下是一种轻度的自限性疾病。最后但同样重要的是，接种COVID-19疫苗的益处超过了目前报告的副作用。
Zotero 插件